目的 觀察鹽酸坦洛新緩釋片聯(lián)合前列康片治療Ⅲ型前列腺炎的臨床療效。方法 選取2014年11月-2015年5月河池市人民醫(yī)院泌尿外科收治的Ⅲ型前列腺炎患者85例,按照隨機數(shù)字表法隨機分為對照組(42例)和治療組(43例)。對照組患者口服前列康片,3片/次,3次/d。治療組患者在對照組基礎(chǔ)上給予鹽酸坦洛新緩釋片,飯后口服,1片/d。兩組患者均連續(xù)用藥6周。觀察兩組患者臨床療效,并比較治療前后NIS-CPSI評分、前列腺液中白細胞計數(shù)、pH值。結(jié)果 治療后,對照組、治療組的總有效率分別為66.67%、86.05%,兩組總有效率比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者疼痛、排尿癥狀、生活質(zhì)量和NIH-CPSI評分均顯著降低,同組治療前后比較差異具有統(tǒng)計學(xué)意義(P<0.05);且治療組這些指標的下降程度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后,兩組患者前列腺液中白細胞計數(shù)、pH值均顯著降低,同組治療前后比較差異具有統(tǒng)計學(xué)意義(P<0.05);且治療組這些指標的下降幅度優(yōu)于對照組,兩組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 鹽酸坦洛新緩釋片聯(lián)合前列康片治療Ⅲ型前列腺炎具有較好的臨床療效,能夠顯著降低NIH-CPSI評分,安全性好,值得在臨床上進一步推廣和應(yīng)用。

Objective To explore the clinical effects of Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets in treatment of typeⅢ prostatitis.Methods Patients (85 cases) with type Ⅲ prostatitis in Department of Urology Surgery of The People's Hospital of Hechi from November 2014 to May 2015 were divided into control (42 cases) and treatment (43 cases) groups according to the random number table method. The patients in the control group were po administered with Qianliekang Tablets, 3 tablets/time, three times daily. The patients in the treatment group were poadministered with Tamsulosin hydrochloride Sustained Release Tablets on the basis of control group, 1 tablet/time, once daily. The patients in two groups were treated for 6 weeks. After treatment, the efficacies were evaluated, and NIS-CPSI scores, white blood cell and pH value of prostatic fluid in two groups before and after treatment were compared.Results After treatment, the efficacies in the control and treatment groups were 66.67% and 86.05%, respectively, and there were differences between two groups (P < 0.05). After treatment, pain, urinary symptoms, quality of life and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, white blood cell counts and pH values of prostatic fluid in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05).Conclusion Tamsulosin hydrochloride Sustained Release Tablets combined with Qianliekang Tablets has clinical curative effect in treatment of typeⅢ prostatitis, can significantly reduce NIH-CPSI scores, higher security, which has a certain clinical application value.